Linden Advisors’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Linden Advisors’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-498,000	Closed	-$5.03M	–	564
2022 Q4	$5.03M	Hold	498,000	–	–	0.05%	209
2022 Q3	$4.94M	Hold	498,000	–	–	0.05%	231
2022 Q2	$4.87M	Hold	498,000	–	–	0.04%	250
2022 Q1	$4.86M	Hold	498,000	–	–	0.03%	342
2021 Q4	$4.83M	Hold	498,000	–	–	0.03%	313
2021 Q3	$4.84M	Hold	498,000	–	–	0.03%	312
2021 Q2	$4.81M	Buy	+498,000	New	+$4.89M	0.03%	342

Linden Advisors's EBAC Position: Q1 2023 in Review

Linden Advisors sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2023, closing a stake of 498,000 shares — an estimated $5.03M sold.

Linden Advisors first reported a position in EBAC in Q2 2021 and held it in 7 quarters. The position peaked at $5.03M in Q4 2022. 0 funds tracked by Wall St. Rank hold EBAC as of Q1 2023.

Linden Advisors reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Linden Advisors sold 498,000 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $5.03M.
Linden Advisors first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q2 2021 and held it in 7 quarters.
Linden Advisors's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $5.03M in Q4 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on Linden Advisors's 13F filing for Q1 2023, filed 15 May 2023.